Cleocin T clindamycin phosphate 10 mg/mL Lotion — NDC 0009-3329-01 (Billing 00009-3329-01)
This is a package of Cleocin T clindamycin phosphate 10 mg/mL Lotion from Pharmacia & Upjohn Company LLC, marketed since May 1989 and currently FDA-listed; retail pharmacies pay about $0.4652 per mL (NADAC). It is this product's only package size.
Other active recalls for Clindamycin Phosphate (different manufacturers) — 6 · tap to view
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 011752
- GCN: 31770
- GPI-14 (Medi-Span): 90051010104105
- HICL (First Databank): 004045
- AHFS class code: 08:12.28.20
- RxCUI (RxNorm): 197519
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 1, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 1, 2026
RxNorm drug class
This medicine belongs to the Lincosamide Antibacterial class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Oct 1, 2026
Clinical
Topical clindamycin is used to treat acne. Clindamycin is in a class of medications called lincomycin antibiotics. It works by slowing or stopping the growth of bacteria that cause acne and by decreasing swelling.
Read the full MedlinePlus article ↗- It treats serious bacterial infections, such as anaerobic infections, skin, lung, abdominal, gynecological, and bone and joint infections, depending on the product. It is often use...
- Swallow them with a full glass of water and stay upright for at least 30 minutes afterward. This helps prevent irritation of your throat. Take it as often as your prescriber says a...
- Rash, nausea, vomiting, stomach pain and itching are among the more commonly reported effects. Call your doctor right away if you get severe, watery or bloody diarrhea, even weeks...
- What side effects are normal, and when should I call you?
Patient education
Supplement & herbal interactions
Clindamycin may be associated with lower levels of 7 nutrients — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 1, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.465 | $27.91 / 60 ml |
| Medicaid paysCMS SDUD · 12 mo | $1.69 | $101.15 / 60 ml |
| Medicare drug plans payPart D · Q2 2026 | $1.89 | $113.65 / 60 ml |
Where does this data come from?
- CMS NADAC weekly file · file of Nov 23, 2022
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · through Q1 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 00009-3329-01 You're viewing this Main listing | 1 BOTTLE in 1 CARTON / 60 mL in 1 BOTTLE | 1989-05-31 | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| clindamycin phosphate 10 mg/mL 00168-0203-60 | E. | 1 bottle | $0.245 | AB | Availability likely | save 47% |
| Clindamycin Phosphate 10 ug/mL 16714-0246-01 | NORTHSTAR | 1 bottle | $0.245 | AB | Availability likely | save 47% |
| Clindamycin Phosphate 10 ug/mL 21922-0036-01 | Encube | 1 bottle | $0.245 | AB | Availability likely | save 47% |
| Clindamycin Phosphate 10 mg/mL 45802-0128-01 | Padagis | 60 ml | $0.245 | AB | Availability likely | save 47% |
| Clindamycin Phosphate 10 mg/mL 51672-1400-04 | Sun | 1 bottle | $0.245 | AB | Availability likely | save 47% |
| clindamycin phosphate 10 mg/mL 59762-3744-01 | Mylan | 1 bottle | $0.245 | AB | Availability likely | save 47% |
| Cleocin T 10 mg/mLthis 00009-3329-01 | Pharmacia | 1 bottle | $0.465 | AB | FDA listed | — |
| Clindamycin Phosphate 10 mg/mL 68682-0462-75 | Oceanside | 1 bottle | $5.280 | AB2 | FDA listed | +1035% |
| Clindamycin Phosphate 10 mg/mL 63629-8632-01 | Bryant | 60 ml | — | AB | FDA listed | — |
| Clindamycin Phosphate 10 mg/mL 63629-9459-01 | Bryant | 60 ml | — | AB | FDA listed | — |
| Clindamycin Phosphate 10 mg/mL 71335-2953-01 | Bryant | 60 ml | — | AB | FDA listed | — |
| Clindamycin Phosphate 10 mg/mL 72162-1395-06 | Bryant | 60 ml | — | AB | FDA listed | — |
| clindamycin phosphate 10 mg/mL 72162-2147-06 | Bryant | 1 bottle | — | AB | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA Orange Book · refreshed Sep 3, 2026
- CMS NADAC weekly file · file of Nov 23, 2022
Availability & generic status
FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.
Where does this data come from?
- FDA Orange Book · refreshed Sep 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 2DMT128M1S
A waxy solid derived from plant or animal sources. It acts as an emulsifier to blend oil and water components, and also thickens the medicine to give it the right texture and consistency.
-
UNII PDC6A3C0OX
Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
-
UNII Q613OCQ44Y
Isostearyl alcohol is a fatty alcohol derived from plant or petroleum sources. It acts as an emollient and thickener in formulations, helping to soften the product and improve texture and stability.
-
UNII A2I8C7HI9T
Methylparaben is a preservative derived from benzoic acid that prevents growth of bacteria, fungi, and mold in medicines. It extends the product's shelf life and maintains safety during storage.
-
UNII 632GS99618
Sodium lauroyl sarcosinate is a mild, plant-derived cleaning agent used in medicines as a surfactant and emulsifier. It helps mix oil and water-based ingredients and may aid tablet disintegration.
-
UNII 4ELV7Z65AP
Stearic acid is a fatty acid derived from plant or animal sources. It acts as a binder and lubricant in tablets and capsules, helping them hold together and flow smoothly during manufacturing.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
7 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 1, 2026
- FDA openFDA NDC Directory · synced Oct 1, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE CLEOCIN T Topical Solution, CLEOCIN T Topical Gel and CLEOCIN T Topical Lotion are indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate (see CONTRAINDICATIONS , WARNINGS and ADVERSE REACTIONS ).
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION Apply a thin film of, CLEOCIN T Topical Lotion, CLEOCIN T Topical Gel, CLEOCIN T Topical Solution, or use a CLEOCIN T Topical Solution pledget for the application of CLEOCIN T twice daily to affected area. More than one pledget may be used. Each pledget should be used only once and then be discarded.
CLEOCIN T Topical Solution is flammable. Avoid fire, flame, and smoking during and immediately following application. Lotion: Shake well immediately before using.
Pledget: Remove pledget from foil just before use. Do not use if the seal is broken. Discard after single use.
Keep all liquid dosage forms in containers tightly closed.
⛔ Contraindications ▾
CONTRAINDICATIONS CLEOCIN T Topical Solution, CLEOCIN T Topical Gel and CLEOCIN T Topical Lotion are contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin, a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis.
⚠️ Warnings ▾
WARNINGS Orally and parenterally administered clindamycin has been associated with severe colitis which may result in patient death. Use of the topical formulation of clindamycin results in systemic absorption from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin.
Studies indicate a toxin(s) produced by clostridia is one primary cause of antibiotic-associated colitis. The colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passage of blood and mucus. Endoscopic examination may reveal pseudomembranous colitis.
Stool culture for Clostridioides difficile and stool assay for C. difficile toxin may be helpful diagnostically. When significant diarrhea occurs, the drug should be discontinued. Large bowel endoscopy should be considered to establish a definitive diagnosis in cases of severe diarrhea.
Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen the condition. Vancomycin has been found to be effective in the treatment of antibiotic-associated pseudomembranous colitis produced by Clostridioides difficile . The usual adult dosage is 500 milligrams to 2 grams of vancomycin orally per day in three to four divided doses administered for 7 to 10 days.
Cholestyramine or colestipol resins bind vancomycin in vitro . If both a resin and vancomycin are to be administered concurrently, it may be advisable to separate the time of administration of each drug. Diarrhea, colitis, and pseudomembranous colitis have been observed to begin up to several weeks following cessation of oral and parenteral therapy with clindamycin.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS In 18 clinical studies of various formulations of CLEOCIN T using placebo vehicle and/or active comparator drugs as controls, patients experienced a number of treatment emergent adverse dermatologic events [see table below]. Number of Patients Reporting Events Treatment Emergent Adverse Event Solution n=553(%) Gel n=148(%) Lotion n=160(%) # not recorded Burning 62 (11) 15 (10) 17 (11) Itching 36 ( 7) 15 (10) 17 (11) Burning/Itching 60 (11) # ( – ) # ( – ) Dryness 105 (19) 34 (23) 29 (18) Erythema 86 (16) 10 ( 7) 22 (14) Oiliness/Oily Skin 8 ( 1) 26 (18) 12 of 126 subjects (10) Peeling 61 (11) # ( – ) 11 ( 7) Orally and parenterally administered clindamycin has been associated with severe colitis which may end fatally.
Cases of diarrhea, bloody diarrhea and colitis (including pseudomembranous colitis) have been reported as adverse reactions in patients treated with oral and parenteral formulations of clindamycin and rarely with topical clindamycin (see WARNINGS ). Abdominal pain, gastrointestinal disturbances, gram-negative folliculitis, eye pain and contact dermatitis have also been reported in association with the use of topical formulations of clindamycin.
🔄 Drug Interactions ▾
Drug Interactions Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents.
🤰 Pregnancy ▾
Pregnancy: Teratogenic Effects In clinical trials with pregnant women, the systemic administration of clindamycin during the second and third trimesters has not been associated with an increased frequency of congenital abnormalities. There are no adequate studies in pregnant women during the first trimester of pregnancy. Clindamycin should be used during the first trimester of pregnancy only if clearly needed.
🧒 Pediatric Use ▾
Pediatric Use Safety and effectiveness in pediatric patients under the age of 12 have not been established.
🧓 Geriatric Use ▾
Geriatric Use Clinical studies for CLEOCIN T did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
🆘 Overdosage ▾
OVERDOSAGE Topically applied CLEOCIN T can be absorbed in sufficient amounts to produce systemic effects (see WARNINGS ).
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Mechanism of Action The mechanism of action of clindamycin in treating acne vulgaris is unknown. Pharmacokinetics Following multiple topical applications of clindamycin phosphate at a concentration equivalent to 10 mg clindamycin per mL in an isopropyl alcohol and water solution, very low levels of clindamycin are present in the serum (0–3 ng/mL) and less than 0.2% of the dose is recovered in urine as clindamycin. Although clindamycin phosphate is inactive in vitro , rapid in vivo hydrolysis converts this compound to the antibacterially active clindamycin.
Microbiology Clindamycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the ribosome. Clindamycin is bacteriostatic. Antimicrobial Activity Clindamycin is active in vitro against most isolates of Propionibacterium acnes; however, the clinical significance is unknown.
Resistance Resistance to clindamycin is most often caused by modification of specific bases of the 23S ribosomal RNA. Cross-resistance between clindamycin and lincomycin is complete. Because the binding sites for these antibacterial drugs overlap, cross-resistance is sometimes observed among lincosamides, macrolides and streptogramin B.
Macrolide-inducible resistance to clindamycin occurs in some isolates of macrolide-resistant bacteria.
🧬 Mechanism of Action ▾
Mechanism of Action The mechanism of action of clindamycin in treating acne vulgaris is unknown.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED CLEOCIN T Topical Solution containing clindamycin phosphate equivalent to 10 mg clindamycin per milliliter is available in the following sizes: 30 mL applicator bottle—NDC 0009-3116-01 60 mL applicator bottle—NDC 0009-3116-02 Carton of 60 single-use pledget applicators—NDC 0009-3116-14 CLEOCIN T Topical Gel containing clindamycin phosphate equivalent to 10 mg clindamycin per gram is available in the following sizes: 60 gram tube—NDC 0009-3331-01 30 gram tube—NDC 0009-3331-02 CLEOCIN T Topical Lotion containing clindamycin phosphate equivalent to 10 mg clindamycin per milliliter is available in the following size: 60 mL plastic squeeze bottle—NDC 0009-3329-01 Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP].
Protect from freezing. CLEOCIN T Topical Solution is flammable. Keep away from heat, sparks or open flames.
📦 Storage and Handling ▾
Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP]. Protect from freezing. CLEOCIN T Topical Solution is flammable. Keep away from heat, sparks or open flames.
📋 Description ▾
DESCRIPTION CLEOCIN T Topical Solution and CLEOCIN T Topical Lotion contain clindamycin phosphate, USP, at a concentration equivalent to 10 mg clindamycin per milliliter. CLEOCIN T Topical Gel contains clindamycin phosphate, USP, at a concentration equivalent to 10 mg clindamycin per gram. Each CLEOCIN T Topical Solution pledget applicator contains approximately 1 mL of topical solution.
Clindamycin phosphate is a water soluble ester of the semi-synthetic antibacterial drug produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent compound lincomycin. The solution contains isopropyl alcohol 50% v/v, propylene glycol, and water. The gel contains allantoin, carbomer 934P, methylparaben, polyethylene glycol 400, propylene glycol, sodium hydroxide, and purified water.
The lotion contains cetostearyl alcohol (2.5%); glycerin; glyceryl stearate SE (with potassium monostearate); isostearyl alcohol (2.5%); methylparaben (0.3%); sodium lauroyl sarcosinate; stearic acid; and purified water. The structural formula is represented below: The chemical name for clindamycin phosphate is Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl- trans -4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L- threo -α-D- galacto -octopyranoside 2-(dihydrogen phosphate). Chemical Structure
⚠️ Precautions ▾
PRECAUTIONS General CLEOCIN T Topical Solution contains an alcohol base which will cause burning and irritation of the eye. In the event of accidental contact with sensitive surfaces (eye, abraded skin, mucous membranes), bathe with copious amounts of cool tap water. The solution has an unpleasant taste and caution should be exercised when applying medication around the mouth.
CLEOCIN T should be prescribed with caution in atopic individuals. Drug Interactions Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents.
Pregnancy: Teratogenic Effects In clinical trials with pregnant women, the systemic administration of clindamycin during the second and third trimesters has not been associated with an increased frequency of congenital abnormalities. There are no adequate studies in pregnant women during the first trimester of pregnancy. Clindamycin should be used during the first trimester of pregnancy only if clearly needed.
Nursing Mothers It is not known whether clindamycin is excreted in breast milk following use of CLEOCIN T. However, orally and parenterally administered clindamycin has been reported to appear in breast milk. Clindamycin has the potential to cause adverse effects on the breast-fed infant's gastrointestinal flora.
Monitor the breast-fed infant for possible adverse effects on the gastrointestinal flora, such as diarrhea, candidiasis (thrush, diaper rash) or rarely, blood in the stool indicating possible antibiotic-associated colitis. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for clindamycin and any potential adverse effects on the breast-fed child from clindamycin or from the underlying maternal condition. Clinical Considerations If used during lactation and CLEOCIN T is applied to the chest, care should be taken to avoid accidental ingestion by the infant.
Pediatric Use Safety and effectiveness in pediatric patients under the age of 12 have not been established. Geriatric Use Clinical studies for CLEOCIN T did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
🍼 Nursing Mothers ▾
Nursing Mothers It is not known whether clindamycin is excreted in breast milk following use of CLEOCIN T. However, orally and parenterally administered clindamycin has been reported to appear in breast milk. Clindamycin has the potential to cause adverse effects on the breast-fed infant's gastrointestinal flora.
Monitor the breast-fed infant for possible adverse effects on the gastrointestinal flora, such as diarrhea, candidiasis (thrush, diaper rash) or rarely, blood in the stool indicating possible antibiotic-associated colitis. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for clindamycin and any potential adverse effects on the breast-fed child from clindamycin or from the underlying maternal condition. Clinical Considerations If used during lactation and CLEOCIN T is applied to the chest, care should be taken to avoid accidental ingestion by the infant.
🧬 Pharmacokinetics ▾
Pharmacokinetics Following multiple topical applications of clindamycin phosphate at a concentration equivalent to 10 mg clindamycin per mL in an isopropyl alcohol and water solution, very low levels of clindamycin are present in the serum (0–3 ng/mL) and less than 0.2% of the dose is recovered in urine as clindamycin. Although clindamycin phosphate is inactive in vitro , rapid in vivo hydrolysis converts this compound to the antibacterially active clindamycin.
📄 Package Label / Principal Display Panel ▾
PRINCIPAL DISPLAY PANEL - 30 mL Bottle Label Pfizer NDC 0009-3116-01 Cleocin T ® clindamycin phosphate topical solution, USP 1%* Solution for topical use only 30 mL Rx only PRINCIPAL DISPLAY PANEL - 30 mL Bottle Label
PRINCIPAL DISPLAY PANEL - 30 mL Bottle Carton Pfizer NDC 0009-3116-01 Cleocin T ® clindamycin phosphate topical solution, USP 1%* Solution for topical use only 30 mL Rx only PRINCIPAL DISPLAY PANEL - 30 mL Bottle Carton
PRINCIPAL DISPLAY PANEL - Pledget Packet Pfizer NDC 0009-3116-14 Cleocin T ® clindamycin phosphate topical solution, USP 1%* Pledget for topical use only 1 Pledget Distributed by Pharmacia & Upjohn Co Division of Pfizer Inc, NY, NY 10017 MADE IN CHINA Rx only PRINCIPAL DISPLAY PANEL - Pledget Packet
PRINCIPAL DISPLAY PANEL - 60 Pledget Packet Carton NDC 0009-3116-14 Pfizer Cleocin T ® 1%* clindamycin phosphate topical solution, USP Pledget for topical use only 60 Pledgets Rx only PRINCIPAL DISPLAY PANEL - 60 Pledget Packet Carton
PRINCIPAL DISPLAY PANEL - 60 mL Bottle Label Pfizer NDC 0009-3329-01 Cleocin T ® clindamycin phosphate topical lotion 1%* For topical use only 60 mL Rx only PRINCIPAL DISPLAY PANEL - 60 mL Bottle Label
PRINCIPAL DISPLAY PANEL - 60 mL Bottle Carton Pfizer NDC 0009-3329-01 Cleocin T ® clindamycin phosphate topical lotion 1%* For topical use only 60 mL Rx only PRINCIPAL DISPLAY PANEL - 60 mL Bottle Carton
PRINCIPAL DISPLAY PANEL - 60 gram Tube Label NDC 0009-3331-01 60 gram Rx only Cleocin T ® clindamycin phosphate topical gel For topical use only 1%* Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP]. Protect from freezing. For external use only.
Avoid contact with eyes. See crimp of tube for Expiration Date and Lot Number. DOSAGE AND USE: See accompanying prescribing information. * Each gram contains clindamycin phosphate equivalent to 10 mg (1%) of clindamycin.
Also contains allantoin, carbomer 934P, methylparaben, polyethylene glycol 400, propylene glycol, sodium hydroxide, and purified water. Pfizer Distributed by Pharmacia & Upjohn Co Division of Pfizer Inc, NY, NY 10017 PRINCIPAL DISPLAY PANEL - 60 gram Tube Label
PRINCIPAL DISPLAY PANEL - 60 gram Tube Carton NDC 0009-3331-01 Pfizer Cleocin T ® 1%* clindamycin phosphate topical gel For topical use only 60 gram Rx only PRINCIPAL DISPLAY PANEL - 60 gram Tube Carton
PRINCIPAL DISPLAY PANEL - 30 gram Tube Label NDC 0009-3331-02 30 gram Rx only Cleocin T ® clindamycin phosphate topical gel For topical use only 1%* Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP]. Protect from freezing. For external use only.
Avoid contact with eyes. See crimp of tube for Expiration Date and Lot Number. DOSAGE AND USE: See accompanying prescribing information. * Each gram contains clindamycin phosphate equivalent to 10 mg (1%) of clindamycin.
Also contains allantoin, carbomer 934P, methylparaben, polyethylene glycol 400, propylene glycol, sodium hydroxide, and purified water. Pfizer Distributed by Pharmacia & Upjohn Co Division of Pfizer Inc, NY, NY 10017 PRINCIPAL DISPLAY PANEL - 30 gram Tube Label
PRINCIPAL DISPLAY PANEL - 30 gram Tube Carton NDC 0009-3331-02 Pfizer Cleocin T ® 1%* clindamycin phosphate topical gel For topical use only 30 gram Rx only PRINCIPAL DISPLAY PANEL - 30 gram Tube Carton